Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

Farhad Ravandi, Mona Lisa Alattar, Michael R. Grunwald, +17

Blood

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Detlef Haase, Kristen E. Stevenson, Donna Neuberg, +47

Leukemia

Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

Mikkael A. Sekeres, Megan Othus, Alan F. List, +20

Journal of Clinical Oncology

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer

Remco J. Molenaar, Surbhi Sidana, Tomas Radivoyevitch, +12

Journal of Clinical Oncology

Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

Aziz Nazha, Mayur Narkhede, Tomas Radivoyevitch, +10

Leukemia

Hematological MalignancyTreated PatientsMedicineMixed-phenotype Acute LeukemiaPrognosis +8

Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

Paolo Strati, Hagop M. Kantarjian, Farhad Ravandi, +12

American Journal of Hematology

Hematological MalignancyMyelodysplastic SyndromeMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia +11

hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies

Miguel Gallardo, Hun Ju Lee, Xiaorui Zhang, +12

Cancer Cell

Tumor BiologyOncologyMedicineMalignant Blood DisorderHaploinsufficient Tumor Suppressor +9

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

Eric Padron, Guillermo Garcia‐Manero, Mrinal M. Patnaik, +18

Blood Cancer Journal

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Preetesh Jain, Hagop M. Kantarjian, Aziz Nazha, +10

Blood

The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort

Maximilian Stahl, Michelle DeVeaux, Théo de Witte, +24

Blood Advances

ImmunodeficienciesImmunologyRbc TiImmunotherapyMyeloid Neoplasia +18